Obesity‑drug market shifts from scarcity to channels

The obesity-drug business spent two years looking like a shortage story, with patients hunting for starter doses and pharmacies rationing supply. In April 2026, it started looking more like a distribution story, with drugmakers changing where people buy these medicines, how they are shipped, and what they cost each month. (novonordisk-us.com, novonordisk.com, medical.lilly.com) Novo Nordisk said on March 31 that it launched a multi-month subscription program for Food and Drug Administration-approved Wegovy in the United States, and the company said the program can save patients up to $1,200 a year. That shifts the sale from a one-box-at-a-time pharmacy transaction toward a recurring service model tied to access and retention. (novonordisk-us.com) Novo Nordisk had already been moving in that direction on March 9, when it said it was expanding United States patient access to semaglutide medicines through Hims & Hers after a change in that telehealth company’s glucagon-like peptide-1 business model. The point was not just more marketing; it was plugging a blockbuster obesity drug into a digital prescribing and fulfillment channel that already has millions of online users. (novonordisk-us.com) Then Europe got a logistics change that sounds small until you picture a package on a delivery truck. Novo Nordisk said on April 9 that the European Medicines Agency approved Wegovy injection for delivery at controlled temperatures up to 30 degrees Celsius for up to 48 hours, which lets pharmacies and online partners ship it with less cold-chain complexity. (novonordisk.com, markets.ft.com) That matters because cold-chain drugs are like groceries that need a cooler bag for the whole trip. If a medicine can handle 48 hours at up to 30 degrees Celsius, more sellers can use ordinary delivery networks for the last mile instead of expensive specialist handling. (novonordisk.com, markets.ft.com) Eli Lilly is attacking the same market from a different angle: format and price. Lilly’s once-daily obesity pill, Foundayo, which is the brand name for orforglipron, was approved by the Food and Drug Administration on April 1, 2026, and Lilly says it is now available through LillyDirect, telehealth providers, and United States retail pharmacies. (medical.lilly.com, foundayo.lilly.com) On Lilly’s savings page, the company says self-pay pricing starts at $149 a month through LillyDirect Pharmacy. That gives patients a number that is easy to compare with a gym membership or a monthly streaming bill, and it gives Lilly a direct channel instead of relying only on insurers and wholesalers. (foundayo.lilly.com) The pill also changes the sales pitch because some patients who will not start a weekly injection may try a daily tablet. Lilly still tells patients to use Foundayo with a reduced-calorie diet and increased physical activity, but the convenience of a pill opens a different front in the same race. (foundayo.lilly.com, foundayo.lilly.com) A third pressure point is generic competition, even if it is not fully on shelves yet. Apotex said it received the first United States Food and Drug Administration tentative approval for a generic version of Ozempic, which is semaglutide injection, in partnership with Orbicular. (prnewswire.com) Tentative approval is not the same as a launch, because it usually means the generic has cleared scientific review but is still blocked by patents or exclusivity. Even so, it tells branded drugmakers that the next fight is not just making enough drug; it is defending price, convenience, and preferred channels before lower-cost versions arrive. (fda.gov, prnewswire.com) Put those moves together and the market looks less like a factory bottleneck and more like a retail land grab. Novo Nordisk is building subscriptions and easier shipping around Wegovy, Eli Lilly is using a $149 self-pay pill and LillyDirect to widen the funnel, and generic semaglutide is moving closer in the background. (novonordisk-us.com, novonordisk.com, foundayo.lilly.com, prnewswire.com)